Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2012

View Archived Issues

Novartis identifies new class of compounds for treating cystic fibrosis

Daiichi Sankyo profiles highlights of fiscal 2011

Roche reports novel agents for raising HDL cholesterol

First results for phase II COMPLETE study of eculizumab presented

Genetic basis of TAR syndrome uncovered

Dainippon Sumitomo Pharma updates activities of fiscal 2011

Spanish researchers patent new agents for Gaucher's disease

Novel monoglyceride lipase inhibitors presented by Janssen Pharmaceutica

Elevation Pharmaceuticals reports phase IIb results for EP-101 in COPD

InterMune patents new agents for hepatitis and liver disorders

Cytomedix expands phase II RECOVER-Stroke study

Astellas Pharma and CoMentis present novel compounds for Alzheimer's disease

Biosceptre collaborates with Australian facilities on cancer antibody research

Achaogen provides update on plazomicin and ACHN-975 programs

New inhibitors of serotonin receptor binding synthesized at Epiomed Therapeutics

Abbott presents clinical results for their antiviral candidate ABT-072

Major Alzheimer's disease prevention study commences

Fibrocell Science enters two new agreements

Pfizer reports topline results from phase III Torisel study

Antibodies targeting misfolded Fas receptor protein disclosed

BG Medicine obtains expanded indication for Galectin-3 test in E.U., files for clearance in U.S.

Repros submits documents to FDA for Androxal SPA

Amgen provides updated blinatumomab results

Neuren Pharmaceuticals and FDA hold pre-IND meeting for NNZ-2566

Ark Therapeutics gives update on VEGF-D adenoviral vector treatment study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...